BioSpace News Archive

Avadel Pharmaceuticals Requests Final FDA Approval for LUMRYZ™ (sodium oxybate) extended-release oral suspension

Avadel Pharmaceuticals plc announced today that it has submitted an amendment to the U.S. Food and Drug Administration (“FDA”) requesting final approval for LUMRYZ for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

March 2, 2023
·
6 min read
Pharm Country

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

Krystal Biotech, Inc. announced today that the Company will participate in the 43rd Annual TD Cowen Health Care Conference, which is taking place in Boston from March 6-8.

March 2, 2023
·
1 min read
BioMidwest

Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022

Daxor Corporation, the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December 31, 2022.

March 2, 2023
·
6 min read
Business

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave updates on its business.

March 2, 2023
·
8 min read
Genetown

CureLab Receives $3M from Prominent Biotech Investor Dr. John Ballantyne

The co-founder of Aldevron, Dr. John Ballantyne, has invested $3M in CureLab Oncology and CureLab Veterinary.

March 2, 2023
·
3 min read
Business

The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa Inhibitor

Bristol Myers Squibb (NYSE: BMY) in collaboration with Janssen Pharmaceuticals, Inc. today announced the launch of the Phase 3 Librexia program studying milvexian, an investigational oral factor XIa (FXIa) inhibitor (antithrombotic).

March 2, 2023
·
8 min read
Business

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates.

March 2, 2023
·
12 min read
Business

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023

Precision BioSciences, Inc. today announced that it will publish financial results for the fourth quarter and fiscal year 2022 and provide a business update on March 9, 2023.

March 2, 2023
·
1 min read
Business

Madison Core Laboratories Ranks No. 185th on Inc. Magazine’s 2023 List of the Southeast Region’s Fastest-Growing Private Companies

Madison Core Laboratories Ranks No. 185th on Inc. Magazine’s 2023 List of the Southeast Region’s Fastest-Growing Private Companies.

March 2, 2023
·
4 min read
Business

Herbert Boyer, Pioneering Geneticist and Co-founder of Today’s Biotech Industry, Joins GATC Health’s Board of Advisors

GATC Health Corp announced that Herbert Boyer has joined GATC Health’s board of advisors.

March 2, 2023
·
3 min read